Viewing nowCombinationJanux XR Extended-Release Tablet 50/500 mg (Sitagliptin, Metformin)
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.

MFDS item code 202201873 · Approved 2022.05.09 · Insurance code 649703020,653806560
Improves blood glucose control in type 2 diabetes
This medication helps control blood sugar levels in patients with type 2 diabetes by the combined action of sitagliptin and metformin. When used in conjunction with diet and exercise regimens, it can effectively improve blood sugar levels. Therefore, this medication is used to enhance blood glucose control in type 2 diabetes patients.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken once daily with a meal, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take one tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug treatment and inadequate glycemic control with monotherapy, or patients inadequately controlled with sitagliptin monotherapy, the initial dose of this medicine is a total daily dose of sitagliptin 100 mg and metformin 1000 mg. If this initial dose does not provide adequate glycemic control, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients inadequately controlled with metformin monotherapy is a total daily dose of sitagliptin 100 mg and the patient's current metformin dose. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release tablets once daily. 3. Patients inadequately controlled with combination therapy with metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is a total daily dose of sitagliptin 100 mg, and the initial metformin dose should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment In patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, this medicine may be used with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1,000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.
This medication contains both sitagliptin and metformin. Sitagliptin can rarely cause serious allergic reactions, so if symptoms such as rash, difficulty breathing, or swelling of the face or lips occur after taking it, you must stop taking it immediately and consult a doctor. Additionally, sitagliptin can cause pancreatitis, which is inflammation of the pancreas, so if symptoms such as abdominal pain, nausea, vomiting, or fever occur, you should inform a healthcare professional immediately. Metformin can cause lactic acidosis, a rare but potentially fatal metabolic disorder, so if symptoms such as sudden muscle pain, difficulty breathing, fatigue, or abdominal pain appear, you should stop taking it immediately and visit a hospital. This medication should not be administered to patients with moderate to severe renal impairment, those with acute cardiovascular disease or acute infection, and women who are pregnant or nursing. Moreover, this medication must be discontinued before undergoing procedures using iodine contrast agents, and can only be resumed after kidney function is confirmed to be normal following the procedure. During treatment, it is essential to have regular kidney function and blood tests, and it’s recommended to periodically check vitamin B12 levels. This medication may interact with other hypoglycemic agents, alcohol, and certain medications, so you must inform your doctor or pharmacist if you are taking any other medications. Hypoglycemia may occur, so meals should be regular, sudden exercise or skipping meals should be avoided, and sugar should be consumed immediately in case of hypoglycemic symptoms. If surgery is planned, the medication should be stopped 48 hours before the procedure, and can be resumed only after kidney function is confirmed to be normal post-surgery. During treatment with this medication, if severe joint pain or skin blisters or rashes occur, you must notify a doctor immediately and receive treatment. Elderly patients are at increased risk of reduced kidney function, thus dosage adjustments and regular examinations are necessary. The safety and efficacy of this medication in children and adolescents under 18 years old have not been sufficiently proven, hence use is not recommended.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly sealed container to prevent exposure to air and moisture. The recommended storage temperature is between 1 and 30 degrees Celsius. Proper storage ensures the long-term efficacy and safety of the medication.
Bright blue, oval, bilayered extended-release film-coated tablet
28 tablets/bottle, 30 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Hunguk Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.